INNOVATIVE healthcare solutions provider Novartis Malaysia has been awarded ‘Sponsor of the Year’ in the annual Clinical Research Malaysia (CRM) Sponsored Research Awards for its outstanding contribution to Malaysia’s clinical research ecosystem.

Novartis Malaysia won the award for contributing the highest number of new studies in 2022. This is the fourth year running that the company has led as top sponsor of new studies.

In 2022, Novartis Malaysia invested in 24 new clinical trials (CT) in cardio-metabolic, breast cancer, spinal muscular atrophy, leukaemia, multiple sclerosis and ophthalmology. About 209 local patients were enrolled in these trials.

In the same year, the company invested circa RM53.56 mil in 79 ongoing studies which amounts to over 25% of the total study value in Malaysia. The award was presented by Health Minister Dr Zaliha Mustafa.

“We are honoured to have been awarded ‘Sponsor of the Year’ by CRM, a site management organisation owned by the Health Ministry (MOH). This recognition further validates our commitment to reimagine medicine to improve and extend people’s lives,” commented Novartis Malaysia’s country president Mohamed Elwakil.

Novartis Malaysia has been supportive in strengthening the country’s healthcare, particularly in the area of clinical research and trials.

“We are glad to be associated with the government’s initiative in enhancing local capabilities, improving clinical trial quality and increasing access to transformative treatment in the country,” shared Elwakil.

“Moving forward, we will continuously grow our engagement with the government and support in strengthening the healthcare system through clinical research and the smart use of digital and technological innovations that apply Real World Evidence (RWE) to guide solutions that can improve patient journeys.”

Meanwhile, CRM’s CEO Dr Akhmal Yusof said Novartis Malaysia was acknowledged as Top Sponsor for 2022 through the high number and contract value of clinical trials that the organisation has brought into the country.

“The conduct of various therapeutic clinical trials initiated by Novartis addresses the unmet medical needs of our patients, providing early access to innovative treatment and improve the health outcome of patients in clinical trials,” noted Akhmal.

“Malaysia’s value proposition as a clinical trial destination of choice is attributed to highly committed clinical investigators, strong regulatory oversight, delivery of good quality clinical trial data and a streamlined process of conducting clinical trials in the country.” - June 7, 2023

https://focusmalaysia.my/novartis-malaysia-recognised-as-sponsor-of-the-year-for-highest-number-of-new-clinical-studies/